BeOne Medicines - ADR opened lower at $369.77, compared with its previous close of $371.56. In the last trading session, the stock traded between $369.77 and $376.45. It showed a sideways intraday trend.
An investment of $100 made 2 years ago in BeOne Medicines - ADR is now worth
$ 203.01
giving a profit of
$ 103.01 (103.01%)
Note: Past profits do not guarantee future returns.
Rating from 13 Analysts
Today's Change
+$1.98 (+0.53%)
Day High
$376.45
Day Low
$369.77
Day Open
$369.77
Prev Close
$371.56
Volume
96,635
1W Return
-2.29%
1M Return
2.25%
3M Return
14.17%
6M Return
28.45%
1Y Return
18.64%
Market Cap ($ Mn)
41,010
PE Ratio
65.60
PB Ratio
8.01
PEG Ratio
-
ROE
7.51%
ROCE
8.69%
EPS (TTM)
$0.16
1 Week
-2.29%
1 Month
2.25%
3 Months
14.17%
6 Months
28.45%
9 Months
6.73%
Truist Securities raises BeOne Medicines price target to $420
Truist Securities raised the price target for BeOne Medicines to $420. The new target represents an increase from the previous $418. The firm maintained its Buy rating on the stock.
23 days agoBeOne Medicines completes pCPA negotiations for TEVIMBRA in Canada
BeOne Medicines completed pCPA negotiations for TEVIMBRA in first-line recurrent or metastatic nasopharyngeal carcinoma on September 25, 2026. No publicly funded first-line immunotherapy option currently exists for this condition in Canada. Nasopharyngeal carcinoma incidence is below 1 per 100,000 in most regions but reaches ~10 per 100,000 in certain Inuit communities.
24 days agoBeOne Medicines to present at Morgan Stanley healthcare conference
BeOne Medicines to present at Morgan Stanley Annual Global Healthcare Conference on September 14, 2026. Fireside chat scheduled for 11:30 am EDT. Live webcast available on company investor relations website.
1mo agoBeOne Medicines signs voluntary US government deal to expand cancer drug access
BeOne Medicines signed a voluntary agreement with the U.S. Government to expand access to cancer medicines. The deal strengthens the company's U.S. manufacturing footprint and expands delivery capabilities. BeOne secured an exemption from Section 232 pharmaceutical tariffs through an onshoring agreement. The company invested $300 million in a Hopewell, NJ facility, part of over $1 billion in total U.S. manufacturing investment.
1mo agoZiihera shows significant survival benefit in Phase 3 cancer trial
Ziihera plus chemo showed statistically significant OS benefit in Phase 3 trial. Second interim analysis met remaining primary endpoint vs trastuzumab plus chemo. TEVIMBRA plus Ziihera regimen showed improved OS hazard ratio and durable outcomes. Trial included 914 patients across 30+ countries for HER2+ gastroesophageal adenocarcinoma.
2mo agoBeOne, Max Foundation renew partnership to support 1,000 CLL patients
BeOne Medicines and The Max Foundation renewed their partnership through 2028 to treat approximately 1,000 CLL patients in low- and middle-income countries. Building on the treatment of over 300 patients since 2023, the initiative expands access to BRUKINSA with a $1 million grant from the BeOne Care Foundation.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 | |
| $174.00 | -25.13% | $23,282.77M | 39.98 |
An investment of $100 made 2 years ago in BeOne Medicines - ADR is now worth
$ 203.01
giving a profit of
$ 103.01 (103.01%)
Note: Past profits do not guarantee future returns.
